Evidence map›Paper›PMID 26379143›Full record

SynthesisPLoS neglected tropical diseases2015

Global Morbidity and Mortality of Leptospirosis: A Systematic Review.

Federico Costa, José E Hagan, Juan Calcagno, Michael Kane, Paul Torgerson, Martha S Martinez-Silveira, Claudia Stein, Bernadette Abela-Ridder, Albert I Ko

2 registry-linked trialsOpen access · goldAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,001 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,001citing papers in PubMed, 7 pooled it
74.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03912506 completednot on this mapstarted 2017, after this paper: background citation

Severe Leptospirosis in Non-tropical Areas: a Nationwide, Multicentre, Retrospective Study in French ICUs

TypeobservationalSponsorNantes University HospitalRan2017 to 2018Enrolled160ConditionsLeptospirosis, Intensive Care Unit, Epidemiology, Alveolar Hemorrhage
NCT07127718 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Decreasing Leptospirosis Emergence Through Prognosis and Treatment Optimization (DeLEPTO) Project 1: Preventive Strategies for Early and Late Complications of Leptospirosis

TypeinterventionalSponsorNational Kidney and Transplant Institute, PhilippinesRan2024 to 2027Enrolled678ConditionsLeptospirosisArmsProphylactic Plasma Transfusion, Hemoperfusion, Extracorporeal Membrane Oxygenation, Conventional therapy
3 · Its place in the literature

Who cites it

1,001 citing papers in PubMed, 7 syntheses or guidelines pooled it, 1,901 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Corticosteroids for treatment of leptospirosis.The Cochrane database of systematic reviews · 2025
    Pooled it
  7. Pooled it
  8. A systematic review ofOne health (Amsterdam, Netherlands) · 2026
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

941 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Federico CostaOswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil; Institute of Collective Health, Federal University of Bahia, UFBA, Salvador, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
José E HaganOswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
Juan CalcagnoOswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil.
Michael KaneCenter for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut, United States of America.
Paul TorgersonSection of Epidemiology, Vetsuisse Faculty, University of Zürich, Zürich, Switzerland.
Martha S Martinez-SilveiraOswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil.
Claudia SteinDivision of Information, Evidence, Research and Innovation, World Health Organization, Regional Office for Europe, UN City, Copenhagen Ø, Denmark.
Bernadette Abela-RidderDepartment for the Control of Neglected Tropical Diseases, World Health Organization, Genève, Switzerland.
Albert I KoOswaldo Cruz Foundation, Brazilian Ministry of Health, Salvador, Bahia, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, United States of America.
Fundação Oswaldo Cruz · BRYale University · USMinistério da Saúde · BRUniversity of Zurich · CHWorld Health Organization · CHWorld Health Organization Regional Office for Europe · DK

Funding

Fogarty International Clinical Research Scholars Support Center @ Vanderbilt-AAMCR24TW007988 · FIC · VANDERBILT UNIVERSITY · PI VERMUND, STEN H. · 2007 to 2011
$27.6M
Research Mentoring and Building Capacity of underrepresented Minority Research Scientists in India.D43TW010540 · FIC · YALE UNIVERSITY · PI MICHELE BARRY, Eva Harris · 2017 to 2026
$15.5M
Infectious Diseases/Basic Microbial Pathogenic MechanismsT32AI007172 · NIAID · WASHINGTON UNIVERSITY · PI Daniel E. Goldberg, JENNIFER A PHILIPS · 1985 to 2026
$13.0M
Naturally-Acquired and Vaccine-Mediated Immunity to LeptospirosisR01AI121207 · NIAID · YALE UNIVERSITY · PI KO, ALBERT ICKSANG, REIS, MITERMAYER GALVAO DOS · 2016 to 2020
$6.4M
Global Health Fellows and Scholars Research TrainingR25TW009338 · FIC · UNIVERSITY OF CALIFORNIA BERKELEY · PI BARRY, MICHELE, KO, ALBERT ICKSANG · 2012 to 2016
$5.2M
Disease Determinants of Urban LeptospirosisU01AI088752 · NIAID · YALE UNIVERSITY · PI KO, ALBERT ICKSANG · 2010 to 2014
$3.6M
Natural History of Urban LeptospirosisR01AI052473 · NIAID · YALE UNIVERSITY · PI KO, ALBERT ICKSANG · 2003 to 2013
$2.8M
Ecoepidemiology of leptospirosis in the urban slums of BrazilR01TW009504 · FIC · YALE UNIVERSITY · PI BEGON, MICHAEL, CHILDS, JAMES EMORY · 2012 to 2016
$2.2M
INTERNATIONAL TRAINING &RESEARCH IN EMERGING INFECTIOUSD43TW000919 · FIC · YALE UNIVERSITY · PI KO, ALBERT ICKSANG · 1997 to 2007
$1.2M
FIC NIH HHS D43 TW000919FIC NIH HHS D43 TW00919FIC NIH HHS D43 TW010540FIC NIH HHS R01 TW009504FIC NIH HHS R24 TW007988FIC NIH HHS R25 TW009338NIAID NIH HHS R01 AI052473NIAID NIH HHS R01 AI121207NIAID NIH HHS T32 AI007172NIAID NIH HHS U01 AI088752Wellcome TrustWellcome Trust 102330/Z/13/ZWorld Health Organization 001
6 · The paper itself

Abstract

backgroundLeptospirosis, a spirochaetal zoonosis, occurs in diverse epidemiological settings and affects vulnerable populations, such as rural subsistence farmers and urban slum dwellers. Although leptospirosis is a life-threatening disease and recognized as an important cause of pulmonary haemorrhage syndrome, the lack of global estimates for morbidity and mortality has contributed to its neglected disease status. METHODOLOGY/PRINCIPAL

findingsWe conducted a systematic review of published morbidity and mortality studies and databases to extract information on disease incidence and case fatality ratios. Linear regression and Monte Carlo modelling were used to obtain age and gender-adjusted estimates of disease morbidity for countries and Global Burden of Disease (GBD) and WHO regions. We estimated mortality using models that incorporated age and gender-adjusted disease morbidity and case fatality ratios. The review identified 80 studies on disease incidence from 34 countries that met quality criteria. In certain regions, such as Africa, few quality assured studies were identified. The regression model, which incorporated country-specific variables of population structure, life expectancy at birth, distance from the equator, tropical island, and urbanization, accounted for a significant proportion (R(2) = 0.60) of the variation in observed disease incidence. We estimate that there were annually 1.03 million cases (95% CI 434,000-1,750,000) and 58,900 deaths (95% CI 23,800-95,900) due to leptospirosis worldwide. A large proportion of cases (48%, 95% CI 40-61%) and deaths (42%, 95% CI 34-53%) were estimated to occur in adult males with age of 20-49 years. Highest estimates of disease morbidity and mortality were observed in GBD regions of South and Southeast Asia, Oceania, Caribbean, Andean, Central, and Tropical Latin America, and East Sub-Saharan Africa. CONCLUSIONS/SIGNIFICANCE: Leptospirosis is among the leading zoonotic causes of morbidity worldwide and accounts for numbers of deaths, which approach or exceed those for other causes of haemorrhagic fever. Highest morbidity and mortality were estimated to occur in resource-poor countries, which include regions where the burden of leptospirosis has been underappreciated.

Indexed as

Age FactorsAnimalsGlobal HealthHumansIncidenceLeptospirosisMortalityNeglected DiseasesSex FactorsSurvival AnalysisZoonoses

Identifiers

PMID26379143
PMCPMC4574773
OpenAlexW1948094720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.